Subjects were not to have a history or presence of significant cardiovascular, pulmonary, hepatic, renal, haematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease. 
Subjects were not to have any history or presence or family history of schizophrenia, other psychotic illness, severe personality disorder, depression, or other significant psychiatric disorder. 
Subjects were not to have a postural drop of 20 mmHg or more in systolic blood pressure at screening. 
Subjects were not to have participated in a previous clinical trial within 90 days prior to study initiation. 
Subjects were not to have donated plasma within 90 days prior to study initiation. 
Subjects were not to have donated blood within 90 days prior to study initiation. 
Subjects were not to have had an abnormal diet or substantial changes in eating habits within 30 days prior to study initiation. 
Subjects were not to have had treatment with any known enzyme-altering agents (barbiturates, phenothiazines, cimetidine etc.) within 30 days prior to or during the study. 
Subjects were to have no history of known hypersensitivity or idiosyncratic reaction to the study drug or related compounds. 
Subjects were not to use any prescription medication within 14 days prior to or during the study. 
Subjects were not to use any over-the-counter medication within 7 days prior to or during the study. 
Subjects were not to have a history of alcohol or drug abuse within 2 years prior to the study (subjects with a history of previous use of cannabis were not excluded unless they had used cannabis or cannabinoid based medicine within 30 days prior to study drug administration or were unwilling to abstain for the duration of the study).       
    

NCT01322464_exc_T2
Condition
schizophrenia
NCT01322464_exc_T3
Condition
psychotic illness
NCT01322464_exc_T4
Condition
severe personality disorder
NCT01322464_exc_T6
Condition
depression
NCT01322464_exc_T7
Condition
psychiatric disorder
NCT01322464_exc_T8
Qualifier
significant
NCT01322464_exc_T10
Observation
family history
NCT01322464_exc_T11
Observation
history
NCT01322464_exc_T12
Observation
presence
NCT01322464_exc_T13
Scope
history or presence or family history
NCT01322464_exc_T14
Scope
schizophrenia, other psychotic illness, severe personality disorder, depression, or other significant psychiatric disorder
NCT01322464_exc_T15
Measurement
systolic blood pressure
NCT01322464_exc_T16
Value
postural drop of 20 mmHg
NCT01322464_exc_T17
Temporal
at screening
NCT01322464_exc_T18
Temporal
90 days prior to study initiation
NCT01322464_exc_T19
Observation
participated in a previous clinical trial
NCT01322464_exc_T21
Procedure
donated plasma
NCT01322464_exc_T22
Temporal
within 90 days prior to study initiation
NCT01322464_exc_T23
Reference_point
study initiation
NCT01322464_exc_T24
Negation
not
NCT01322464_exc_T25
Negation
not
NCT01322464_exc_T26
Procedure
donated blood
NCT01322464_exc_T27
Negation
not
NCT01322464_exc_T28
Temporal
within 90 days prior to study initiation
NCT01322464_exc_T29
Reference_point
study initiation
NCT01322464_exc_T30
Observation
abnormal diet
NCT01322464_exc_T31
Observation
changes in eating habits
NCT01322464_exc_T32
Qualifier
substantial
NCT01322464_exc_T33
Temporal
within 30 days prior to study initiation
NCT01322464_exc_T34
Reference_point
study initiation
NCT01322464_exc_T35
Scope
abnormal diet or substantial changes in eating habits
NCT01322464_exc_T36
Negation
not
NCT01322464_exc_T37
Drug
enzyme-altering agents
NCT01322464_exc_T38
Drug
barbiturates
NCT01322464_exc_T39
Drug
phenothiazines
NCT01322464_exc_T40
Drug
cimetidine
NCT01322464_exc_T41
Temporal
within 30 days prior to or during the study
NCT01322464_exc_T42
Condition
hypersensitivity
NCT01322464_exc_T43
Condition
idiosyncratic reaction
NCT01322464_exc_T44
Drug
study drug
NCT01322464_exc_T45
Negation
no
NCT01322464_exc_T46
Drug
prescription medication
NCT01322464_exc_T47
Temporal
within 14 days prior to the study
NCT01322464_exc_T48
Temporal
during the study
NCT01322464_exc_T49
Scope
within 14 days prior to or during the study
NCT01322464_exc_T50
Negation
not
NCT01322464_exc_T51
Temporal
within 7 days prior to the study
NCT01322464_exc_T52
Temporal
during the study
NCT01322464_exc_T53
Scope
within 7 days prior to or during the study
NCT01322464_exc_T54
Drug
over-the-counter medication
NCT01322464_exc_T55
Negation
not
NCT01322464_exc_T56
Condition
drug abuse
NCT01322464_exc_T57
Condition
alcohol abuse
NCT01322464_exc_T58
Temporal
within 2 years prior to the study
NCT01322464_exc_T59
Reference_point
the study
NCT01322464_exc_T60
Reference_point
the study
NCT01322464_exc_T61
Scope
alcohol or drug abuse
NCT01322464_exc_T62
Observation
history
NCT01322464_exc_T63
Condition
use of cannabis
NCT01322464_exc_T64
Negation
not excluded
NCT01322464_exc_T66
Negation
not